Details of the Drug

General Information of Drug (ID: DMUOK4C)

Drug Name

Lisinopril

Synonyms

Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

405.5

Topological Polar Surface Area (xlogp)

-2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.2 mL/min/kg [4]
Elimination: 94% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 42 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.4092 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 1% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.89 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 97 mg/mL [3]

Chemical Identifiers

Formula: C21H31N3O5
IUPAC Name: (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
Canonical SMILES: C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
InChI: InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
InChIKey: RLAWWYSOJDYHDC-BZSNNMDCSA-N

Cross-matching ID

PubChem CID: 5362119
ChEBI ID: CHEBI:43755
CAS Number: 76547-98-3
DrugBank ID: DB00722
TTD ID: D07HGR
VARIDT ID: DR00991
ACDINA ID: D00370

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin-converting enzyme (ACE)	DTT	SLC33A1	2.62E-01	-0.01	-0.06
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lisinopril

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Lisinopril and Eprosartan.	Hypertension [BA00-BA04]	[24]
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Lisinopril and Aliskiren.	Hypertension [BA00-BA04]	[25]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Lisinopril and TAK-491.	Hypertension [BA00-BA04]	[24]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Lisinopril and Indapamide.	Hypertension [BA00-BA04]	[26]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Lisinopril and Trichlormethiazide.	Hypertension [BA00-BA04]	[26]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Lisinopril and Telmisartan.	Hypertension [BA00-BA04]	[24]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Lisinopril and Irbesartan.	Hypertension [BA00-BA04]	[27]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Lisinopril and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[26]
-----------


⏷ Show the Full List of 8 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lisinopril (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Lisinopril and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[28]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Lisinopril due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[29]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Repaglinide.	Acute diabete complication [5A2Y]	[30]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Glibenclamide.	Acute diabete complication [5A2Y]	[30]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Tolazamide.	Acute diabete complication [5A2Y]	[30]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Nateglinide.	Acute diabete complication [5A2Y]	[30]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Insulin-glulisine.	Acute diabete complication [5A2Y]	[30]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Insulin-aspart.	Acute diabete complication [5A2Y]	[31]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Glipizide.	Acute diabete complication [5A2Y]	[30]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Lisinopril and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[32]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Lisinopril and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[33]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Lisinopril and Cariprazine.	Bipolar disorder [6A60]	[34]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Lisinopril and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[35]
Mannitol	DMSCDY9	Moderate	Additive hypotensive effects by the combination of Lisinopril and Mannitol.	Bronchiectasis [CA24]	[26]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Lisinopril and Olopatadine.	Conjunctiva disorder [9A60]	[36]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Lisinopril and Drospirenone.	Contraceptive management [QA21]	[37]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Lisinopril and Ardeparin.	Coronary thrombosis [BA43]	[24]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Lisinopril and Selegiline.	Depression [6A70-6A7Z]	[38]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Lisinopril and Isocarboxazid.	Depression [6A70-6A7Z]	[38]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Lisinopril and OPC-34712.	Depression [6A70-6A7Z]	[34]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Lisinopril and Phenelzine.	Depression [6A70-6A7Z]	[38]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Lisinopril and Nitroglycerin.	Diabetic foot ulcer [BD54]	[32]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Lisinopril due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[29]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Lisinopril and Ethacrynic acid.	Essential hypertension [BA00]	[39]
Acetazolamide	DM1AF5U	Moderate	Additive hypotensive effects by the combination of Lisinopril and Acetazolamide.	Glaucoma [9C61]	[26]
Dichlorphenamide	DMH7IDQ	Moderate	Additive hypotensive effects by the combination of Lisinopril and Dichlorphenamide.	Glaucoma [9C61]	[39]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Lisinopril and Chlorothiazide.	Heart failure [BD10-BD1Z]	[26]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Lisinopril and Bumetanide.	Heart failure [BD10-BD1Z]	[26]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Lisinopril and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[26]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Lisinopril and Procarbazine.	Hodgkin lymphoma [2B30]	[38]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Lisinopril and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[40]
Didanosine	DMI2QPE	Minor	Decreased absorption of Lisinopril due to altered gastric pH caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Lisinopril and Isosorbide mononitrate.	Hydrocephalus [8D64]	[32]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Lisinopril and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[41]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Lisinopril and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[42]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Lisinopril and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[43]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Lisinopril and Potassium chloride.	Hypo-kalaemia [5C77]	[44]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Lisinopril and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[45]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Lisinopril and Propiomazine.	Insomnia [7A00-7A0Z]	[34]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Lisinopril and ITI-007.	Insomnia [7A00-7A0Z]	[34]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Lisinopril and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[46]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Lisinopril and Idelalisib.	Mature B-cell leukaemia [2A82]	[47]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Lisinopril due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[42]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Lisinopril and Ozanimod.	Multiple sclerosis [8A40]	[38]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Lisinopril and Promethazine.	Nausea/vomiting [MD90]	[34]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Lisinopril and Polythiazide.	Oedema [MG29]	[26]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Lisinopril and Safinamide.	Parkinsonism [8A00]	[38]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Lisinopril and Rasagiline.	Parkinsonism [8A00]	[38]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Lisinopril and Terazosin.	Prostate hyperplasia [GA90]	[48]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Lisinopril and Silodosin.	Prostate hyperplasia [GA90]	[48]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Lisinopril and Levomepromazine.	Psychotic disorder [6A20-6A25]	[34]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Lisinopril and Leflunomide.	Rheumatoid arthritis [FA20]	[42]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Lisinopril and Quetiapine.	Schizophrenia [6A20]	[34]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Lisinopril and Mesoridazine.	Schizophrenia [6A20]	[34]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Lisinopril and Aripiprazole.	Schizophrenia [6A20]	[34]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Lisinopril and Iloperidone.	Schizophrenia [6A20]	[34]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Lisinopril and Paliperidone.	Schizophrenia [6A20]	[34]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Lisinopril and Perphenazine.	Schizophrenia [6A20]	[34]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Lisinopril and Molindone.	Schizophrenia [6A20]	[34]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Lisinopril and Thiothixene.	Schizophrenia [6A20]	[34]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Lisinopril and Trifluoperazine.	Schizophrenia [6A20]	[34]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Lisinopril and Risperidone.	Schizophrenia [6A20]	[34]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Lisinopril and Amisulpride.	Schizophrenia [6A20]	[34]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Lisinopril and Asenapine.	Schizophrenia [6A20]	[34]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Lisinopril and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[49]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of hyperkalemia by the combination of Lisinopril and Tacrolimus.	Transplant rejection [NE84]	[50]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[30]
Liraglutide	DM3FXPS	Minor	Altered absorption of Lisinopril due to GI dynamics variation caused by Liraglutide.	Type 2 diabetes mellitus [5A11]	[51]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Lisinopril and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[30]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Lisinopril and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[34]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Lisinopril and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[52]
-----------


⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium phosphate	E00298	24456	Anticaking agent; Buffering agent; Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lisinopril 10 mg tablet	10 mg	Oral Tablet	Oral
Lisinopril 20 mg tablet	20 mg	Oral Tablet	Oral
Lisinopril 30 mg tablet	30 mg	Oral Tablet	Oral
Lisinopril 40 mg tablet	40 mg	Oral Tablet	Oral
Lisinopril 5 mg tablet	5 mg	Oral Tablet	Oral
Lisinopril 2.5 mg tablet	2.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6360).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
7	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
8	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
9	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
10	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
11	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
12	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
13	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
14	Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
15	Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
16	Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
17	Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
18	Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
19	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
20	Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
21	Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
22	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
23	Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
24	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
25	Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
26	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
27	Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
30	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
31	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
32	Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
33	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
34	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
35	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
36	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
37	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
38	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
39	Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
40	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
41	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
42	Canadian Pharmacists Association.
43	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
44	Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
45	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
46	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
47	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
48	Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
49	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
50	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
51	Product Information. Victoza (liraglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
52	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.